GIA632 / Novartis - LARVOL DELTA

ELIPSI: A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus (clinicaltrials.gov) - P2 | N=259 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Dermatopathology • Lichen Planus

ELIPSI: A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus (clinicaltrials.gov) - P2 | N=259 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Dermatology • Dermatopathology • Lichen Planus

CGIA632B12201: A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo (clinicaltrialsregister.eu) - P1/2 | N=59 | Not yet recruiting | Sponsor: Novartis Pharma AG

New P1/2 trial • Dermatology • Immunology • Vitiligo

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=34 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=84 ➔ 34

Enrollment change • Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

VITESS: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=210 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Vitiligo

CGIA632A12201: Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis (clinicaltrialsregister.eu) - P1/2 | N=52 | Recruiting | Sponsor: Novartis Pharma AG

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

VITESS: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=210 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Dermatology • Immunology • Vitiligo

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology